Clinical Trial Update: Bioequivalence Study Comparing Rifampicin In A Fixed-Dose Combination (Rifampicin+Isoniazid, Myrin© 2) And The Reference Drug (Rifampicin, Rimactane®) [Phase 1]

View source ↗

Summary

A Phase 1 bioequivalence study compared a fixed-dose combination of rifampicin and isoniazid (Myrin 2) with rifampicin alone (Rimactane) to assess pharmacokinet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis

Drugs mentioned

• Myrin 2 (rifampicin + isoniazid fixed-dose combination)
• Rimactane (rifampicin)

Snippet

Sponsor: Pfizer | Conditions: Tuberculosis | Phase 1 | Status: COMPLETED | Results posted: 2012-07-30